Generic Zyrtec Recalled Over Heartburn Drug Mix-Up, July 23

Unique Pharmaceutical Laboratories is recalling four lots of generic Zyrtec (cetirizine hydrochloride 5-mg tablets) nationwide after discovering contamination with ranitidine, a heartburn medication. A pharmacy technician spotted red-colored pills mixed in while counting the antihistamine tablets. For people allergic to ranitidine, ingestion could trigger anaphylaxis and other life-threatening reactions. No adverse events have been reported to date.

What was contaminated and how it was found

The recall affects cetirizine hydrochloride tablets USP 5-mg distributed by Rising Pharma Holdings Inc. in 100-tablet bottles. Four lot numbers are involved: GY825029, GY825030, GY825031, and GY825032, all expiring October 2028. A pharmacy technician discovered the issue while counting pills before dispensing them to a customer, noticing red dots and discolored tablets mixed among the white antihistamine pills.

Why this matters for people with ranitidine allergies

The FDA warns that consumers with hypersensitivity to ranitidine face serious risk. Ingesting contaminated tablets could cause anaphylaxis, hypotension, shortness of breath, difficulty swallowing, throat swelling, and loss of consciousness. These reactions are life-threatening. People without ranitidine allergies face minimal risk from the contamination.

How to check if you have recalled medication

Check the lot number on the side of your cetirizine bottle. If it matches GY825029, GY825030, GY825031, or GY825032, do not use it. Contact Rising Pharma Holdings at 1-844-874-7464 from 8 a.m. to 5 p.m. ET Monday through Friday, or email [email protected] or [email protected]. The company will arrange returns and replacements.

Pfizer connection and market impact

Pfizer does not manufacture the recalled generic version. Unique Pharmaceutical Laboratories, a division of J.B. Chemicals & Pharmaceuticals Ltd., produced it. Pfizer’s brand-name Zyrtec remains unaffected. Pfizer stock closed at $25.01 on July 23, up 0.77% on the day. Meyka rates PFE a B (Neutral) with a 12-month forecast of $28.71, suggesting limited upside from current levels.

Final Thoughts

The recall affects only four specific lot numbers of generic cetirizine. People without ranitidine allergies face minimal risk. Check your bottle’s lot number and contact Rising Pharma if it matches. Pfizer’s branded Zyrtec is unaffected.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.